Under the terms of the agreement, Alexion and Zealand Pharma entered into an exclusive collaboration for the discovery and development of subcutaneously delivered peptide therapies directed to up to four complement pathway targets. Revenue increased, but the company generated another net loss -- a much steeper loss, in fact, than Wall Street expected. We have continued our clinical trials while working with authorities, investigators, trial sites and contract research organizations to minimize site visits and ensure optimal trial follow-up. We can supply you with accurate and up-to-date information on companies throughout the country. Fundet i bogen – Side 745DRUG - FOOD INTERACTIONS see FOOD - DRUGNTERA TIONS DRUG FORMULATION see CHEMISTRY , PHARMACEITICAL PRCG HABITUATION see ... Antibiotic development pipeline runs dry . ... Biomate- New Zealand moves to ban direct advertising of drugs . Zealand Pharma is developing treatments for gastrointestinal diseases, with a current focus on short bowel syndrome (SBS). You should not place undue reliance on these statements, or the scientific data presented. Zealand Pharma A/S is a Denmark-based biopharmaceutical company engaged in the discovery, development and commercialization of peptide-based medicines. Participants are advised to register for the webcast approximately 10 minutes before the start. For more information about Zealand’s business and activities, please visit http://www.zealandpharma.com. However, it is Managementâs opinion that the amount of any payment cannot be determined on a sufficiently reliable basis, and therefore the company has not recognized an asset in the statement of financial position of the Group. The following potential ordinary shares are anti-dilutive and are therefore excluded from the weighted average number of ordinary shares for the purpose of diluted earnings/loss per share: Outstanding warrants under the 2010 Employee incentive program, Outstanding warrants under the 2015 Employee incentive program, Outstanding warrants under the 2020 Employee incentive program, Outstanding Performance Share Units (PSUs) under the LTIP 2019 program, Outstanding Restricted Share Units (RSUs) under the LTIP 2020 program, Outstanding Performance Share Units (PSUs) under the LTIP 2021 program, Outstanding Restricted Share Units (RSUs) under the LTIP 2021 program. Copenhagen, March 11, 2020 - Zealand Pharma A/S ("Zealand") (NASDAQ: ZEAL) (CVR-no. Fundet i bogen – Side 318New Zealand , Jan - May 1999 ; Chrm , MBA for Sci . and Tech . , Sch . of Bus . , Queen's University , 1999 to date . ... CAREER : Acctnt , Ernst & Young , 11 yrs .; Special Projects Mgr , Astra Pharma Inc. , 1989-90 ; Cont . , 1990-95 ... The third Phase 2 randomized double-blind placebo-controlled dose-finding trial will evaluate BI 456906 in people with NASH and liver fibrosis (F2/F3) with and without diabetes (ClinicalTrials.gov Identifier: NCT04771273). In addition, top-line results of a post bariatric hypoglycemia Phase 2a dose-finding clinical proof of concept trial were reported in 2020 and showed that mini doses of dasiglucagon reduced meal-induced hypoglycemia compared to placebo in individuals who had undergone gastric bypass bariatric surgery. However, we have not recognized any write-offs, impairments of assets, or losses to onerous contracts due to COVID-19. The auditor performs procedures primarily consisting of making enquiries of Management and others within the company, as appropriate, applying analytical procedures and evaluate the evidence obtained. Pipeline Zealand Pharma is a world leader in peptide drug discovery and design, building upon 20 years of experience in understanding and exploiting peptide design. Although our clinical studies continued without interruption during 2021 and 2020, there were delays and increased total costs arising from the implications of COVID-19. (2) Equity ratio is calculated as equity at the balance sheet date divided by total assets at the balance sheet date. Dasiglucagon for bi-hormonal artificial pancreas pumps. Since the 12 months period has expired all amounts are assessed to be final and no further adjustments relating to the business combination can occur. Company announcement - No. Zealand Pharma (Nasdaq: ZEAL) is a biotechnology company focused on the discovery, development, and commercialization of next generation peptide-based medicines that change the lives of people . Zealand Pharma and Alexion Pharmaceuticals announced in March 2019 that they will collaborate on the discovery and development of novel peptide therapies for complement-mediated diseases. The Company's pipeline comprises two . With one product on the market, one candidate in registration and six candidates in the clinical pipeline, Zealand is a unique success story in Danish biotech. Zealand Pharma A/S (Zealand) is a fast-growing, fully integrated Copenhagen-based biotechnology company with a highly attractive pipeline. He just wants to sell $TSLA,â the investor made fam. The condensed interim financial statements are prepared in accordance with IAS 34 Interim Financial Reporting, as issued by the International Accounting Standards Board (IASB) and as adopted by the EU, and additional requirements of the Danish Financial Statements Act. The bill is being drafted by South Carolina Republican Nancy Mace, and discussion has been going. On 23 January 2020 Protagonist Therapeutics filed a demand for arbitration with the International Court of Arbitration of the International Chamber of Commerce (ICC) seeking a declaration that it has no past, present or future milestone or royalty payment obligations with respect to the compound it is advancing, PTG-300, alleging that the compound is not within the set of compounds to which such payment obligations apply. The U.S. FDA granted orphan drug designation to glepaglutide for the treatment of SBS. The total number of treasury shares as of June 30, 2021 is 284,223 and will be used for long term incentive compensation plans. It was founded on 1 April 1997 and currently has over 200 employees. The earnings/loss and weighted average number of ordinary shares used in the calculation of basic and diluted earnings/loss per share are as follows: Net earnings/loss used in the calculation of basic earnings/loss per share, Weighted average number of ordinary shares, Weighted average number of treasury shares, Weighted average number of ordinary shares used in the calculation of basic/diluted loss per share. Approximately 350 adults and 350 children with type 1 diabetes will be randomized into the Phase 3 trial. Further in June 2021, the Company started a share buyback program with an expected purchase of 154,187 shares or for an amount up to DKK 32,070,896. 30 70 02 28, Christian Schwenn Johansen State Authorized Public Accountantmne33234, Rasmus Bloch JespersenState Authorized Public Accountantmne35503, Interim condensed consolidated financial statements. BI 456906 GLP-1/GLU Dual Agonist. Buying a stock is easy, but purchasing the right stock without a proven strategy is incredibly hard. Equity ratio is calculated as equity at the balance sheet date divided by total assets at the balance sheet date. Today Zealand Pharma convenes its Annual General Meeting 2021 #WithZeal Due to the Valeritas asset purchase agreement closing in April 2020, product revenue for V-Go in the H1 2020 is only for the last three months of the period. The condensed consolidated interim financial statements are prepared in accordance with IAS 34 Interim Financial Reporting, as issued by the International Accounting Standards Board (IASB) and as adopted by the EU, and additional requirements of the Danish Financial Statements Act. We are conducting additional analyses and engaging with regulatory authorities to discuss the results of 17109 while awaiting the outcome of a second Phase 3 trial, 17103, in neonates up to 12 months old with CHI. We have made notable progress across our pipeline in the first half of the year, and with multiple clinical milestones on the horizon in the second half of the year, we are well positioned to achieve our goal of offering five marketed products by 2025.â. As a world leader in innovative peptide therapeutics, Zealand Pharma is committed to our bold and ambitious pipeline. Top-line results from a Phase 2a dose-finding trial in people with type 1 diabetes were presented at the American Diabetes Association congress in June 2021. Fundet i bogen... Replacement: Development: Y Generics: TYPES OF BUSINESS: Pharmaceuticals Acquisition & Development Drugs-Hematology & Oncology ... The deal includes MGCD0103, MethylGene's lead HDAC inhibitor, as well as MethylGene's pipeline of ... New standards, interpretations and amendments adopted by the Group. The net income tax income is mainly impacted by the tax deduction in Denmark, a prior period correction offset by the taxable income in US. Announced the initiation of two Phase 2 trials for BI 456906 by partner Boehringer Ingelheim and Fast Track Designation from the U.S. FDA. Fundet i bogen – Side 150IFIP WG 8.2 Working Conference, IS&O 2014, Auckland, New Zealand, December 11-12, 2014, Proceedings Bill Doolin, ... reductions in the pipeline of new medicines entering the market and the 'patent cliff' off which large pharma companies ... Register now for our 11/17 webinar at 2PM ET, Zealand Pharma Launches ZEGALOGUE® (dasiglucagon) Injection and Advances Pipeline Programs Across Multiple Therapeutic Areas. 03 / 2020 Zealand Pharma advances pipeline and maintains strong cash position: full year results for 2019 Copenhagen, March 11, 2020 - Zealand Pharma A/S ("Zealand") (NASDAQ: ZEAL) (CVR-no. We maintain compliance with guidance from applicable government and health authorities as appropriate. Most Read from BloombergWhat Designers of Video Game Cities Understand About Real CitiesAmazon Sued Over Crashes by Drivers Rushing to Make DeliveriesBiden Plan Funds New Bridges That Locals May Not WantHong Kong's New Museum Tries to Please Art World â and BeijingMusk even raised the notion of sel. NOTE: DKK/USD Exchange rates used: June 30, 2021 = 6.257 and June 30, 2020 = 6.6553, INCOME STATEMENT AND COMPREHENSIVE INCOME, Earnings/loss per share â basic/diluted (DKK), Cash, cash equivalents and Marketable securities, Cash outflow/inflow from operating activities, Cash outflow/inflow from investing activities, Cash outflow/inflow from financing activities, Purchase of property, plant and equipment, Number of full-time employees at the end of the period. Fundet i bogen – Side 251281 Brand Precision Bl , Inc. Rust l ional Inc Bridgeport Center For Clinical Studies, Inc. Pharmakinetics Brand ... Bridge Oil Philippines, Inc. Bridge Oil USA Inc. 253 Bridge Oil Pipeline Company, Inc. Bridge Oil USA Inc 253 Bridge ... Note 4 â Administrative, sale and marketing expenses. Fundet i bogen – Side 327Transactions Magyar Filozofiai Szemle ( HU ) Journal of Pipelines ( NE ) Pipeline Wissenschaften ( GW ) Chinese Studies in ... Neoscolastica ( IT ) New Zealand Journal of Geology and Pharmaprojects ( UK ) Societe Geologique du Nord . In a report dated Nov. 10 and prepared for the big United Nations climate conference that just concluded in Glasgow, BloombergNEF projects annual EV sales to hit 5.6 million in 2021, up from 3.1 million in 2020. Zealand Pharma will lead the joint discovery and research efforts through the preclinical stage, and Alexion will lead development efforts beginning with IND filing and Phase 1 trials. President of Zealand Pharma U.S. Frank holds a Bachelor of Arts from Wittenberg University. If approved by the FDA, the dasiglucagon auto-injector and pre-filled syringe could become the first dasiglucagon-based medicine made Out-patient Phase 2 trials in exercise-induced hypoglycemia in people living with type 1 diabetes and for people that suffer from meal-induced hypoglycemia following gastric bypass surgery were initiated in the second quarter this year (ClinicalTrials.gov Identifier: NCT04764968 and NCT04836273) and the first subjects have been enrolled into the out-patient Phase 2 trial evaluating effectiveness of pen-administered low-dose dasiglucagon for prevention and treatment of hypoglycemia in people with type 1 diabetes. The potential for chronic dasiglucagon infusion delivered via a pump to prevent hypoglycemia in children with CHI is being evaluated in a Phase 3 program. About Zealand Pharma A/S. (4) Market capitalization is calculated as outstanding shares at the balance sheet date times the share price at the balance sheet date. Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines. New Zealand with our easily searchable database. Fundet i bogen – Side 484... Ltd 322 New Zealand Oil & Gas Ltd 223 New Zealand Petroleum Co Ltd 224 , 373 New Zealand Refining 310 New Zealand ... Exploration ( Thailand ) Ltd 241 NOMECO Holdings Ltd 241 NOMECO New Zealand Exploration Co 241 NOMECO Pipeline Co ... On December 18, 2020 Amyndas Pharmaceuticals S.A. and Amyndas Pharmaceuticals LLC filed a complaint in the U.S. District Court for the District of Massachusetts, which named Alexion Pharmaceuticals, Inc., Zealand Pharma A/S and Zealand Pharma U.S., Inc. as defendants. The acquisition increased Zealand Pharma's personnel by 110 employees in the US and added the V-Go program to the Zealand commercial portfolio. Results showed a plasma half-life allowing for once weekly dosing. As of June 30, 2021, Zealand is still eligible for a payment from Sanofi of up to USD 10.0 million which is expected in 2022. Actual results may differ from these estimates. The increase in other liabilities is mainly related to a one-off liability regarding purchase of treasury shares of DKK 45.3 million.
In the preparation of the interim condensed consolidated financial statements, the Companyâs management (âManagementâ) makes several accounting estimates that form the basis for the presentation, recognition and measurement of the Companyâs assets and liabilities. Is Intel Stock A Buy After Chipmaker's Third-Quarter Earnings Report? In particular, the global COVID-19 pandemic could potentially materially adversely impact our business and financial performance, including the timing of our clinical trials, projected regulatory approval timelines, our supply chain and sales of our approved products, as well as our Financial Guidance for 2021 in this interim report, particularly because the COVID-19 pandemic continues to evolve, and its breadth and significance on our business and financial performance is uncertain. (2) Equity ratio is calculated as equity at the balance sheet date divided by total assets at the balance sheet date. The program has received Fast Track designation from the U.S. FDA. Fundet i bogenPartnership potential The federal government announced grants totalling $ 28 million to pharmaceutical companies partnering local biotechnology ... senior medical director of Pfizer Australia and New Zealand , Dr Bill Ketelbey , says . Our business, operations and clinical studies were, of course, impacted by the effects of COVID-19. Most Read from BloombergWhat Designers of Video Game Cities Understand About Real CitiesAmazon Sued Over Crashes by Drivers Rushing to Make DeliveriesBiden Plan Funds New Bridges That Locals May Not WantHong Kong's New Museum Tries to Please Art World â and BeijingâHe doesnât need cash. Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines. Cash, cash equivalents, and marketable securities: DKK 1,282.9 million / USD 205.0 million as of June 30, 2021 (June 30, 2020: DKK 1,665.0 million / USD 250.2 million). Fundet i bogen – Side 23It has gives it access to the HBJ pipeline . " We remain already broken ground for its ... It first acquired Karvol , in the decongestive inhalant anti - cold segment , from Solvay Pharma for a total consideration of Rs9.37 crore . Based on our review, nothing has come to our attention that causes us to believe that these interim condensed consolidated financial statements are not prepared, in all material respects, in accordance with IAS 34 Interim Financial Reporting, as issued by the International Accounting Standards Board (IASB) and as adopted by the EU, and additional requirements of the Danish Financial Statements Act. The pandemic impacted the speed of patient recruitment for our Phase 3 trial with glepaglutide for the treatment of short bowel syndrome, and results are expected in 2022. We continuously monitor the COVID-19 pandemic and its potential impact on our business and financials. Encycle Therapeutics provides technology to synthesise macrocyclic peptides with drug-like properties. NOTE: DKK/USD Exchange rates used: June 30, 2021 = 6.257 and June 30, 2020 = 6.6553. So you should expect to hear more from that, as I mentioned. COVID-19 restrictions have not affected our phase 3-program for dasiglucagon in congenital hyperinsulinism (CHI) and we expect topline data from the second Phase 3 trial in 2021. For the lead target, Zealand Pharma is eligible to receive up to USD 610 million in development and sales milestone payments, plus royalties on global sales in the high single to low double digits. Net sales in US for the six months period ended June 30, 2021 comprise DKK 101.5 million including license revenues and sale of goods. Fundet i bogen – Side 346See New Zealand White ... See also Big pharma Pharmaceutical industry, 316 Pharmaceutical R&D productivity crisis, 227 IND application, 228 opportunities for earlier decision making, 228 traditional drug development, 227, ... Fundet i bogen – Side 368Zealand Pharma pipeline information. November 2017. https://www.zealandpharma.com/longacting-amylin-a. Introduction Obesity and diabetes have become worldwide epidemics. Obesity is 368 N. C. Kaarsholm. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market. Zealand Pharma, Zealand Pharma Launches ZEGALOGUE® (dasiglucagon) Injection and Advances Pipeline Programs Across Multiple Therapeutic Areas. Cash used in investing activities in the first six months of 2021 related mainly to acquisition of tangible assets. The third Phase 2 randomized double-blind placebo-controlled dose-finding trial will evaluate BI 456906 in people with NASH and liver fibrosis (F2/F3) with and without diabetes (ClinicalTrials.gov Identifier: NCT04771273). # # # About Zealand Pharma A/S Zealand Pharma A/S (Nasdaq: ZEAL) a biopharmaceutical company, is developing next generation peptide-based medicines to change the lives of people living with . The program has received Fast Track designation from the U.S. FDA. In 2021 a reversal of previous periods estimated write-down on prelaunch inventory with a net positive income statement effect of DKK 25.1 million on research and development expenses was recognized, as a consequence of our FDA approval of Zegalogue. Fundet i bogen – Side 8Mabs for the ELISA - based gastric cand In terms of innovation , pharmaceutical test and hopes to get it into the clinic with pricing differences mean that the ... Filling pharma's R & D pipeline of non - small - cell - lung cancer . Other investments consist of a USD 5.4 million (December 31, 2020: USD 5.4 million) investment in Beta Bionics, Inc., the developer of iLet™, a fully integrated dual-hormone pump (bionic pancreas) for autonomous diabetes care. Its Stock Is a Good Long-Term Bet. Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines. Chipmaking giant Intel has had a rough 2021, which has rocked INTC stock. Fundet i bogen – Side 581They strived to discover and develop a pipeline of drug candidates with the potential to be best-in-class globally and ... BeiGene had four assets in clinical development in the United States, Australia, New Zealand, and China. In the H1 of 2020 Zealand only had the sales and marketing expense and infrastructure effective April 2020 following the Valeritas asset purchase agreement. Management’s statement on the interim report. The auditor performs procedures primarily consisting of making enquiries of Management and others within the company, as appropriate, applying analytical procedures and evaluate the evidence obtained. Our business, operations and clinical studies were, of course, impacted by the effects of COVID-19. Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines. Here you will find details of pharmaceutical companies in. The increase was mainly driven by the capital increase in January 2021 amounting to DKK 748.9 million offset by cash spent in the period. Participants are advised to register for the webcast approximately 10 minutes before the start. Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, development, and commercialization of peptide-based medicines. On July 6, 2021 Amyndas moved the District Court to reconsider its dismissal of the claims against Zealand Pharma A/S (and its U.S. subsidiary). This transaction will immediately provide substantial value and secure funding for development of Zealand's fully-owned product pipeline. As the payment is not due yet, a liability of DKK 41.6 million is recognized under other liabilities. The company's head office is situated in Søborg near Copenhagen, and it has close to 200 employees.In 2018 they opened a subsidiary in the US. Product pipeline. Such statements are subject to risks and uncertainties as various factors, some of which are beyond the control of Zealand, may cause actual results and performance to differ materially from the forecasts made in this interim report. Electric vehicles are the future. Accordingly, we do not express an audit opinion on the interim condensed consolidated financial statements. Adjustment of foreign currency fluctuations on subsidiaries, Interim condensed consolidated statements of cash flow for the six months periods ended June 30, 2021 and 2020 and for the twelve months period ended December 31, 2020, Acquisition of Valeritas business, net of cash acquired, Proceeds from issuance of shares related to exercise of share-based compensation, Decrease/increase in cash and cash equivalents, Cash and cash equivalents by beginning of period, Cash and cash equivalents by end of period, Interim condensed consolidated statements of financial position as of June 30, 2021 and December 31, 2020, Interim condensed consolidated statements of changes in equity for the six months periods ended June 30, 2021 and 2020, Other comprehensive income for the period, Note 1 - Basis of preparation and changes to the Groupâs accounting policies.
The interim condensed consolidated financial statements of Zealand Pharma A/S (“the Company”) have been prepared in accordance with IAS 34, Interim Financial Reporting, as issued by the International Accounting Standards Board (IASB) and as adopted by EU and additional requirements of the Danish Financial Statements Act. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions, which may cause actual results to differ materially from expectations set forth herein and may cause any or all of such forward-looking statements to be incorrect, and which include, but are not limited to, unexpected costs or delays in clinical trials and other development activities due to adverse safety events or otherwise; unexpected concerns that may arise from additional data, analysis or results obtained during clinical trials; our ability to successfully market both new and existing products; changes in reimbursement rules and governmental laws and related interpretation thereof; government-mandated or market-driven price decreases for our products; introduction of competing products; production problems; unexpected growth in costs and expenses; our ability to integrate operate businesses in varying geographies; failure to protect and enforce our data, intellectual property and other proprietary rights and uncertainties relating to intellectual property claims and challenges; regulatory authorities may require additional information or further studies, or may reject, fail to approve or may delay approval of our drug candidates or expansion of product labeling; failure to obtain regulatory approvals in other jurisdictions; exposure to product liability and other claims; interest rate and currency exchange rate fluctuations; unexpected contract breaches or terminations; and the direct and indirect impacts of the ongoing COVID-19 pandemic on our business, results of operations and financial condition. Direct engagement with health care providers and patients has been reduced and transformed by leveraging virtual meetings, training, and support. Jonathan Livingston Havmåge er en smuk og tankevækkende fortælling om havmågen Jonathan, der afviger fra sin flok. Han kan ikke indordne sig dens normer; han vil det frie og uafhængige liv. Morgan Stanley Says Steer Clear of U.S. Stocks and Bonds in 2022, These Are The Best Robinhood Stocks To Buy Or Watch Now. Zealand Pharma A/S was founded in 1998 and is a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines. Announced publication of Phase 3 trial results evaluating efficacy and safety of dasiglucagon for treatment of severe hypoglycemia in adult patients with diabetes. However, we have not recognized any write-offs, impairments of assets, or losses to onerous contracts due to COVID-19. This success is based on our deep understanding of peptide chemistry and extensive experience in improving the therapeutic characteristics of naturally-occurring peptides by modifying and optimizing their structures. Zealand is managed and operated as one business unit, which is reflected in the organizational structure and internal reporting. Net sales in Germany amounts to DKK 30.7 million including license and milestone revenue.
A more extensive description of risk factors can be found in the 2020 Annual Report under the section Risk management and internal control. ET3764 is an oral, peptide drug designed to . In the application of the Companyâs accounting policies, Management is required to make judgments, estimates and assumptions about the carrying amounts of assets and liabilities that are not readily apparent from other sources. Intangible assets of DKK 55.3 million recognized as at June 30, 2021 as compared to DKK 57.5 million as of December 31, 2020. Royalty expense relates to cost to 3rd parties in connection with the Sanofi royalty agreement. Zealand Pharma A/S (Zealand) is a fast-growing, fully integrated Copenhagen-based biotechnology company with a highly attractive pipeline. In our opinion, the interim report gives a true and fair view of the Group’s assets, equity and liabilities and financial position at June 30, 2021 as well as of the results of the Group’s operations and cash flow for the period January 1 – June 30, 2021. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market. The total number of treasury shares as of June 30, 2021 is 284,223 and will be used for long term incentive compensation plans. In April 2021, Zealand and Boehringer Ingelheim announced the initiation of two Phase 2 trials for the GLP-1/glucagon dual agonist for adults who are overweight or obese, and for adults with non-alcoholic steatohepatitis (NASH). This interim report contains forward-looking statements, including forecasts of future expenses as well as expected business-related events. The reduction in costs related to Zegalogue is partially offset by costs incurred by our late-stage clinical programs for dasiglucagon and glepaglutide. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market. We have adapted the way we work to support our community’s efforts to reduce the transmission of COVID-19 and protect our employees, while continuing to provide patient care and maintain business continuity. Conference call today at 4 pm CEST / 10 am EDT. Product pipeline — Zealand pharma. Pipeline. At CIRTA 2021, Zealand presented three posters, including data on glepaglutide that suggested dose adjustment may not be necessary when treating short bowel syndrome (SBS) patients with renal impairment. Zealand Pharma forms part of the Danish-Swedish life science cluster .